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Differential chemosensitivity to antifolate drugs
between RAS and BRAF melanoma cells
Imanol Arozarena1*, Ibai Goicoechea2†, Oihane Erice3†, Jennnifer Ferguson1, Geoffrey P Margison4
and Claudia Wellbrock1*
Abstract
Background: The importance of the genetic background of cancer cells for the individual susceptibility to cancer
treatments is increasingly apparent. In melanoma, the existence of a BRAF mutation is a main predictor for
successful BRAF-targeted therapy. However, despite initial successes with these therapies, patients relapse within a
year and have to move on to other therapies. Moreover, patients harbouring a wild type BRAF gene (including 25%
with NRAS mutations) still require alternative treatment such as chemotherapy. Multiple genetic parameters have
been associated with response to chemotherapy, but despite their high frequency in melanoma nothing is known
about the impact of BRAF or NRAS mutations on the response to chemotherapeutic agents.
Methods: Using cell proliferation and DNA methylation assays, FACS analysis and quantitative-RT-PCR we have
characterised the response of a panel of NRAS and BRAF mutant melanoma cell lines to various chemotherapy
drugs, amongst them dacarbazine (DTIC) and temozolomide (TMZ) and DNA synthesis inhibitors.
Results: Although both, DTIC and TMZ act as alkylating agents through the same intermediate, NRAS and BRAF
mutant cells responded differentially only to DTIC. Further analysis revealed that the growth-inhibitory effects
mediated by DTIC were rather due to interference with nucleotide salvaging, and that NRAS mutant melanoma cells
exhibit higher activity of the nucleotide synthesis enzymes IMPDH and TK1. Importantly, the enhanced ability of
RAS mutant cells to use nucleotide salvaging resulted in resistance to DHFR inhibitors.
Conclusion: In summary, our data suggest that the genetic background in melanoma cells influences the response
to inhibitors blocking de novo DNA synthesis, and that defining the RAS mutation status could be used to stratify
patients for the use of antifolate drugs.
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Background
Cutaneous melanoma is a deadly form of skin cancer that
develops from melanocytes, specialized pigmented cells
that reside underneath the epidermis. 50% of melanomas
harbour activating mutations in the kinase BRAF, the most
common being a V600E substitution [1], and 25% harbour
mutations in the GTPase NRAS. Both oncogenes stimulate
the MAP-kinase (MAPK)-pathway, which is found hyper-
activated in 90% of all melanomas [2]. Whereas BRAF only
activates the MAPK-pathway, NRAS activates several other
effectors including Ral-GDS or PI3-kinase, which is of spe-
cial relevance for melanoma [2].
It is now accepted that genetic lesions in BRAF and
NRAS have different consequences in melanoma forma-
tion and it is becoming apparent that BRAF can regulate
invasion and metastasis through mechanisms different to
NRAS [3].
Importantly, the genetic background of melanoma also
impacts on the response to therapies targeting the MAPK-
pathway. While there is no efficient targeted therapy against
wild type BRAF melanomas, BRAF mutant (mutBRAF)
melanomas are addicted to the MAPK-pathway and small
molecule inhibitors targeting either mutBRAF or MEK
have shown impressive clinical responses [4-7]. Unfortu-
nately, these responses are transient, and patient relapse
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due to acquired resistance [8]. In contrast to mutBRAF
melanomas, mutNRAS tumours are largely resistant to
BRAF inhibitors [9,10], and moreover these drugs para-
doxically stimulate the MAPK-pathway [11]. Thus, despite
the initial successes with BRAF targeted therapy, relapsed
patients as well as the 50% of patients harbouring a wild
type BRAF (including the 25% with NRAS mutations) will
still require alternative treatment such as chemotherapy
and/or immunotherapy.
In melanoma some of the most commonly used chemo-
therapeutics are the monofunctional-alkylating agents
dacarbazine (DTIC) and temozolomide (TMZ), the chloro-
ethylating agents carmustine or the bifunctional alkylating
agents like cisplatin [12]. Also anti-mitotic drugs like pac-
litaxel and vinblastine are used in the treatment of melan-
oma patients (www.cruk.org). Historically the prodrug
DTIC has been the first line treament with an average
overall response of 20% [12]. In patients DTIC is metabo-
lized in the microsomes of hepatocytes into MTIC, which
undergoes spontaneous transformation into a toxic DNA
methylating agent [13]. More recently patients are being
treated with Temozolomide (TMZ), which does not re-
quire metabolic activation, but spontaneously converts
into MTIC and shows a clinical response almost identical
to DTIC [13,14].
Notably, compared to brain tumors, melanoma responses
to alkylating agents are poor. In patients with malignant
melanoma, the overall response to temozolomide is around
15% compared to 47 and 61% in glioma and astrocytoma
patients [12,15]. Interestingly mutBRAF melanoma patients
have shown responses to DTIC of up to 23% [16] but, on
the other hand, recent reports state that activating muta-
tions in BRAF have no impact on the response of stage IV
melanoma patients to DTIC or TMZ [17]. However, BRAF
and NRAS mutation status has never been tested retro-
spectively for its potential as predictive marker for DTIC
responses. Resistance to these alkylating agents is thought
to be due to several factors, including the altered ex-
pression of components of the apoptotic and DNA
damage repair machineries and to multi-drug resistance
phenotype-associated proteins such as the ABC drug
transporters [18-20]. Pre-clinical studies using melan-
oma and glioma cells and xenografts have shown that
expression of the DNA repair protein O6-methylguanine-
DNA-methyl-transferase (MGMT) confers resistance to
mono-alkylating agents such as DTIC, TMZ and carmus-
tine [21]. However, this has not been successfully trans-
lated into the clinic and the use of MGMT inactivating
agents to sensitise cancer cells to alkylating drugs has not
provided any clinical benefit [21]. Thus, in contrast to tar-
geted therapy, and despite extensive studies into DNA re-
pair mechanisms in relation to tumour response, there are
no good markers to predict a patients response to chemo-
therapy. Since in melanoma the genetic background
delineates specific mechanisms of proliferation, survival or
invasion/migration and regulates the response of melan-
oma cells to targeted therapy, we hypothesized with the
possibility that mutations in BRAF or NRAS might affect
melanoma cell response to chemotherapeutic agents.
Results
NRAS mutant melanoma cells are less responsive to DTIC
than BRAF mutant cells
To address the potential influence of the genetic back-
ground on the response of melanoma cells to chemo-
therapeutic agents, we tested three different classes of
DNA damaging agents: carmustine, cisplatin and DTIC in
9 NRAS mutant and 9 BRAF mutant melanoma cell lines
(mutNRAS and mutBRAF cells; see Additional file 1:
Table S1). When comparing the mean GI50 for all mutN-
RAS cells with that of mutBRAF cells, no statistically sig-
nificant difference was observed when cells were treated
with carmustine or cisplatin (Figure 1A-B). In contrast,
mutNRAS cells were significantly more resistant to DTIC
than mutBRAF cells (p < 0.001, Figure 1C). In view of this
result we decided to use TMZ as another triazene that acts
on DNA through a mechanism identical to that of DTIC.
Surprisingly, no significant difference was detected be-
tween the average GI50 for TMZ in mutBRAF and mutN-
RAS melanoma cells (Figure 1D).
Light activated DTIC does not act through DNA alkylation
As mentioned TMZ undergoes spontaneous activation,
whereas DTIC needs to be metabolized in the liver [13].
We had activated DTIC by exposure to white light, an al-
ternative in vitro activation method previously described by
others. Indeed we confirmed that light activation enhanced
DTIC-mediated growth inhibition (Additional file 2: Figure
S1A). To establish that this gives rise to a DNA alkylating
agent, we quantified O6meG levels in DNA extracted from
DTIC-treated cells and compared them with the levels in
TMZ-treated cells. As expected, TMZ efficiently induced
DNA methylation (Figure 2A). However, light activated
DTIC even at high concentrations (300 μM), was unable to
induce any detectable DNA methylation in either mut-
BRAF or mutNRAS cell lines (Figure 2A). Furthermore, in
line with the induction of DNA damage, Histone H2AX
phosphorylation was detectable in TMZ treated cells, but
no signal was observed in DTIC treated cells (Figure 2B).
Accordingly, light activated DTIC failed to induce the acti-
vation of CHK-1 and CHK-2, kinases known to be activated
by DNA damage (Additional file 2: Figure S1B).
Because MGMT activity is closely linked to MTIC medi-
ated DNA damage, we determined the levels of MGMT in
selected cell lines. We found no correlation between MGMT
activity and NRAS or BRAF mutation status (Additional file
3: Table S2). However, as expected, MGMT expressing cells
were significantly more resistant to TMZ (Figure 2C), but
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the average GI50 for DTIC was not significantly differ-
ent between MGMT expressing and non-expressing
cells (Figure 2D). Furthermore, A375P cells, which pos-
sess MGMT activity (Additional file 3: Table S2), are
sensitized to TMZ by the MGMT inhibitor lomeguatrib,
whereas lomeguatrib did not have any effect on DTIC
treatment (Figure 2E). Similar results were obtained with
other mutBRAF cells as well as with several mutNRAS cell
lines including WM1361 (Figure 2E). These data indicate
that light-activated DTIC, unlike TMZ, cannot induce
DNA alkylation, and that the differential growth inhibitory
activities observed in BRAF and NRAS mutant melanoma
cells are due to alternative mechanisms.
Light activated DTIC induces a G1 cell cycle arrest
To gain more insight into the effect of DTIC on melanoma
cell growth we analysed cell cycle progression in the pres-
ence of light activated DTIC and compared this to TMZ
treatment. Exposure to TMZ for 72 hours led to a signifi-
cant G2/M arrest in both mutBRAF D10 cells and mutN-
RAS MM485 cells (Figure 3A and B). On the other hand,
DTIC treatment with a concentration equivalent to the
average GIC50 of all mutBRAF cells (50 μM) led to block
at the G1/S-transition in mutBRAF D10 cells (Figure 3A).
Moreover, mutNRAS MM485 cells were largely unaffected
by DTIC (Figure 3B). Similar results where obtained with
other mutBRAF and mutNRAS melanoma cell lines (data
not shown). We then analysed whether the accumulation
in G1 was linked to a reduction in DNA synthesis and in-
deed, when we treated mutBRAF WM266-4 cells with
DTIC for 24, 48 or 72 h, there was a progressive reduction
in DNA synthesis, with a maximal inhibition of 65% at 72 h
(Figure 3C).
Hypoxanthine overcomes the DTIC mediated growth
inhibition in melanoma cells
The observation of a DNA synthesis phenotype was in-
triguing, because white light exposure of DTIC triggers
its degradation to 2-aza-hypoxanthine (2-AzaHX) [22],
which can interfere with DNA synthesis. Thereby 2-
AzaHX competes with the structurally related hypoxan-
thine (HX) as substrate for the hypoxanthine-guanine
phosphoribosyltransferase (HGPRT) in the purine sal-
vage pathway (Figure 4A).
To assess the possibility that DTIC was transformed into
2-AzaHX, we analysed the UV absorption spectrum of
DTIC and observed that light exposure of DTIC led to the
formation of a metabolite with maximal UV absorption at
256-295 nm, similar to that of 2-AzaHX (Additional file 4:
Figure S2).
Next we treated the melanoma cell lines with DTIC in
the presence of HX, which should compete with 2-AzaHX
Figure 1 Mutation dependent response to alkylating agents. Nine melanoma cell lines with activating mutations in either BRAF or RAS were
treated with serial increasing concentrations of A, carmustine B, cisplatin, C, dacarbazine (DTIC) or D, temozolomide (TMZ). After 5 days, cells
were quantified using toluidine blue staining. Untreated cells were set 100% and the GI50 for each drug was calculated as the mean of 3
independent measurements. Each point corresponds to an individual cell line. Student’s t test compares the average GI50 for mutBRAF cell lines
vs mutNRAS cell lines. ns = not significant, ***p = 0.0006 for DTIC MutBRAF vs mutRAS cells.
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Figure 2 Light activated DTIC does not methylate DNA. A, Cells were treated with 300 μM DTIC for 24 h or 1 mM TMZ for 3 h, cells were
harvested, genomic DNA purified and equal amounts of gDNA were used to determine the level of DNA methylation. ND: not detectable. B, Cells
were treated with 300 μM DTIC or 1 mM TMZ for 24 h and stained for γH2AX by immunofluorescence. C and D, Cell lines were grouped upon
their MGMT status (MGMT + ve = MGMT proficient; MGMT-ve =MGMT deficient), and the average GI50 for TMZ or DTIC was compared between
both groups. Student’s t test compares the average GI50 for MGMT + ve cells vs MGMT-ve cell. n.s.: not significant, *p < 0.05. MGMT + ve cells are
significantly more resistant to TMZ than MGMT-ve cells, p = 0.0116. E, Dose response curve of cell survival to TMZ or DTIC in the absence (DMSO)
or presence of the MGMT inhibitor lomeguatrib (LOM, 20 μM). A375 or WM1361 cells were treated with lomeguatrib 1 h before addition of different
concentrations of DTIC or TMZ. After 5 days cells were stained with toluidine blue and quantified. DMSO treated cells were set as 100%. The GI50 for
each combinatorial treatment is shown.
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for HGPRT binding and prevent its inhibitory effect. In-
deed, the addition of HX significantly overcame the ef-
fects of DTIC in WM266-4 cells, increasing the GI50 to
DTIC by almost 15-fold (Figure 4B). Moreover, in the
presence of HX, the average GI50 for DTIC in mut-
BRAF cells was comparable to that of mutNRAS melan-
oma cells in the absence of HX (~300 μM, Figure 4C).
Notably, when mutNRAS melanoma cells were treated
with 300 μM DTIC HX addition also reverted the
growth effects (Figure 4D), suggesting that DTIC in-
hibits the purine salvage pathway also in these cells. In
support of this finding, the addition of 5-guanosine
monophosphate (GMP) or guanosine (GR) rescued the
inhibitory effect of DTIC in mutBRAF and mutNRAS
cells (Figure 4E). These results support the hypothesis
that the growth inhibitory effect of light activated DTIC
is mediated by its degradation to 2-AzaHX, which in-
hibits the purine salvage pathway.
NRAS mutant melanoma cells display higher nucleotide
salvage pathway activity than BRAF mutant cells
Nucleotide salvage pathways are crucial for efficient DNA
synthesis, particularly in fast dividing cells. In line with
this, we found increased expression of the key enzymes of
nucleotide salvaging HGPRT (HPRT1), thymidine kinase
(TK1) and APRT in melanoma (primary and metastatic)
Figure 3 Light activated DTIC blocks melanoma cell proliferation. A and B, DNA content FACS analysis of D10 and MM485 cell lines treated
with TMZ or DTIC for 72 hr. C, Proliferation assay. WM266-4 cells were treated with DTIC or the MEK inhibitor selumetinib and EdU incorporation
was measured 24, 48 or 72 hours after drug addition as indicated; untreated cells were set 100%. One-way Anova was used to compare the effect
of each treatment with untreated cells. *p < 0.05, **p < 0.01, ***p < 0.001.
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compared to normal skin and benign nevi ( Figure 5A).
We then argued that despite the general increased salvage
activities in melanoma cells, mutNRAS cells might exhibit
and even higher efficiency of salvage pathway usage than
mutBRAF cells, which would render them resistant to the
inhibitory effect of 2-AzaHX. To test this hypothesis we
cultured melanoma cell lines in the presence of an inhibi-
tor of de novo DNA synthesis, aminopterin. Under these
conditions cell growth is mainly driven via nucleotide sal-
vage pathways, which is fuelled by the addition of the
Figure 4 The DTIC inhibitory effect is overcome by hypoxanthine. A, Structure of hypoxanthine (HX) and 2-azahypoxanthine (2-AzaHX).
B, Dose response curve of WM266-4 cell survival to DTIC in the absence (vehicle) or presence of 100 μM hypoxanthine (HX). Untreated cells were
set as 100%. C, Graph showing the GI50 for DTIC of six mutBRAF melanoma cell lines treated as in B. The average GI50 for cells co-treated with
HX (336.5 μM) was significantly higher than for vehicle-treated cells (22.89 μM), as determined by Student’s t test. **p = 0.0046. D, Quantification of cell
survival of five mutRAS melanoma cell lines upon treatment with 300 μM DTIC in the absence (vehicle) or presence of 100 μM hypoxanthine (HX). E,
Cell survival of 3 mutBRAF and 3 mutNRAS cell lines treated with 50 μM or 300 μM DTIC respectively in the absence (−) or presence of 100 μM
Guanosine (GR) or 2′5′-GMP (GMP).
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Figure 5 mutNRAS melanoma cells possess increased thymidine salvage capacity. A, Heat map of expression profile of APRT, HPRT1 and
TK1 genes in normal skin, benign nevus and melanoma in a data set obtained from Oncomine [24]. B, Four mutBRAF and mutNRAS melanoma
cell lines were treated with 0.4 μM aminopterine in the absence (A) or presence of hypoxanthine and thymidine (HAT). After 3 days cells were
fixed, stained with toluidine blue and surviving fractions were quantified. C, Four mutBRAF or D, mutNRAS cell lines were grown in normal
medium supplemented with 0.4 μM aminopterin in the presence or absence of 100 μM HX or 16 μM thymidine, as indicated. After 3 days the
survival fraction was determined. Cells cultured in normal medium were set as 100% survival. E-G, Comparison of thymidine kinase (TK1) mRNA
expression in mutBRAF and mutNRAS melanoma cell lines (as assessed by q-RT-PCR) in our panel of melanoma cell lines or in two independent
data sets deposited in Oncomine [25,26]. *p < 0.05, **p < 0.01, ***p < 0.001.
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supplements HX and thymidine 005B [23]. In the presence
of aminopterin, the growth of all cell lines was significantly
reduced (Figure 5B), indicating that de novo DNA synthesis
is required for cell growth. However, whereas the addition
of HX and thymidine almost completely rescued the
growth of mutNRAS cell lines, mutBRAF cell lines did not
show an increase in cell growth (Figure 5B). This suggested
that although mutBRAF cells use salvage pathways for cell
growth when de novo synthesis is inhibited (25% cell
growth after 3 days of inhibition), the efficiency of this alter-
native DNA synthesis route is much lower in these cells
than in mutNRAS cells.
We next quantified the individual effects of adding
HX and thymidine as salvage substrates for HGPRT and
thymidine kinase, respectively. Interestingly, when the
de novo synthesis was inhibited addition of HX alone
did not enhance cell growth in mutNRAS and mut-
BRAF cells (Figure 5C and D), suggesting that under
these conditions the cells might be using endogenously
produced guanine as an alternative substrate [27]. On
the other hand, mutNRAS cells were significantly more
efficient than mutBRAF cells in utilising thymidine to
counteract the growth inhibitory effect of de novo syn-
thesis inhibition (Figure 5C and D).
Thymidine is the substrate of TK1 in the pyrimidine
salvage pathway and our data suggested that TK1 activ-
ity is increased in mutNRAS cells. Indeed, we found a
significant overexpression of TK1 in mutNRAS cells
compared to mutBRAF cells in our panel of melanoma
cell lines (Figure 5E). This finding was supported by two
independent datasets [25,26] analysed in Oncomine
(Figure 5F and G).
NRAS mutant melanoma cells are more resistant to DNA
de novo synthesis inhibitors than BRAF mutant cells
Our data show that in mutNRAS melanoma cells elevated
TK1 activity contributes to enhanced pyrimidine salvaging.
However, the inhibitory effect of 2-AzaHX is on the purine
salvage pathway, where after conversion into 2-Aza-inositol
monophosphate (2-AzaIMP) it suppresses IMP dehydro-
genase (IMPDH) (Figure 6A). Thus, the difference in the
response of mutNRAS and mutBRAF cells to DTIC could
be based on differences in IMPDH. Indeed, mutNRAS cells
were significantly more resistant to two IMPDH inhibitors,
Mycophenolic Acid (MPA) and AVN944, compared to
mutBRAF cells (Figure 6B). IMPDH expression levels did
not differ in the individual cell lines (data not shown), indi-
cating that the resistance in mutNRAS cells is not due to
higher IMPDH expression levels.
In summary, mutNRAS melanoma cells are more effi-
cient in nucleotide salvaging than mutBRAF melanoma
cells, which is at least part due to enhanced TK1 expres-
sion and IMPDH activity (Figure 6A). This finding sug-
gests that mutNRAS melanoma cells would be more
resistant to drugs targeting DNA de novo synthesis than
mutBRAF cells. Indeed, when we determined the GI50 of
our panel of melanoma cells for the DHFR inhibitors ami-
nopterin, pyrimethamine and methrotrexate, we found
that mutNRAS cells were significantly more resistant than
mutBRAF cells (Figure 6C). Moreover, when we analysed
a dataset derived from a drug screen using a large panel of
cancer cell lines [25], we found not only that NRAS mu-
tant melanoma cell lines were more resistant to pyrimeth-
amine than BRAF mutant melanoma cells (Figure 6D),
but that independently of cancer type, mutRAS cancer
cells were significantly more resistant to pyrimethamine
than mutBRAF cells (Figure 6E).
Discussion
The aim of this study was to determine whether the muta-
tional status of melanoma cells would correlate with their
response to chemotherapeutic agents. Our results demon-
strate that in melanoma the presence of mutually exclusive
BRAF and NRAS mutations has no influence on the re-
sponse to DNA alkylating agents such as TMZ. Similar re-
sults considering BRAF or RAS mutation status are found
in a large data set containing drug-treatment data from 732
cancer cell lines of different origin [25]. Thus, it appears
that mutBRAF and mutNRAS share common mechanisms
of resistance to methylating agents such as drug efflux, or
deregulation of pro-apoptotic or DNA repair pathways.
Surprisingly, we found that mutBRAF and mutNRAS
cells respond very differently to light activated DTIC. Acti-
vation of DTIC by exposure to white light has been de-
scribed to recapitulate its chemotherapeutic activity in vitro
[28,29] but our results provide experimental evidence that
the toxic effect described for light activated DTIC is inde-
pendent of DNA methylation. Through DNA alkylation as-
says and combinatorial treatments using DTIC and a
MGMT inhibitor we provide clear evidence that light ex-
posure does not transform DTIC into a DNA methylating
agent, but rather an inhibitor of DNA synthesis. This find-
ing is of major importance considering that light activation
of DTIC has been extensively used to study the mecha-
nisms underlying its cytotoxic effects as well as leading to
acquired resistance in patients [28-31]. In this context it is
important to mention that wild type BRAF melanoma cells
that had been selected for resistance to light activated DTIC
in vitro exhibited increased tumour growth in vivo, a
phenotype that correlates well with enhanced DNA synthe-
sis activity [32]. Most strikingly these resistant cells and
tumours displayed hyper-activation of the MAP-kinase
pathway, resulting in increased IL8 and VEGF expression
[28,32]. The fact that we now show that light activated
DTIC inhibits nucleotide synthesis, most probably by inhi-
biting IMPDH, suggests a novel link between DNA synthe-
sis pathways and MAP-kinase signalling.
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Our results indicate that non-metabolically activated
DTIC mediates its effects through 2-AzaHX. Strikingly,
there is evidence that metabolic activation of DTIC in
patients is inefficient and that, shortly after DTIC iso-
lated limb perfusion, significant amounts of 2-AzaHX
can be detected in the bloodstream and urine of pa-
tients [33]. Thus it is possible that 2-AzaHX could con-
tribute to the DTIC-dependent toxicity, although it is
well established that the anti-tumour activity of DTIC is
mainly the result of DNA methylation [13].
In this context it is important to mention that con-
version of 2AzaHX by HGPRT to 2-AzaIMP is able to
inhibit IMPDH [34,35]. We found that mutNRAS mel-
anoma cells are significantly more resistant to two
bona fide IMPDH inhibitors (MPA and AVN944), sug-
gesting that in NRAS mutant cells IMPDH activity or
its downstream signalling is elevated. This, together
with the fact that mutNRAS cells express higher levels
of TK1 and consequently are more effective in using
thymidine for DNA synthesis, provides strong evidence
Figure 6 mutRAS melanoma cells are more resistant to DHFR targeting drugs. A, Schematic of nucleotide de novo synthesis and salvage
pathways. The asterisks indicate increased activity (IMPDH) or expression (TK1) in mutNRAS cells. B, Average survival of 4 mutBRAF or mutNRAS
cell lines after treatment with 4 μM Mycophenolic Acid (MPA) or 5 μM AVN499. **p = 0.01, ***p < 0.001. C, Melanoma cell lines with activating
mutations in either BRAF or NRAS were treated with serial increasing concentrations of aminopterin, pyrimethamine or methotrexate. After
3 days, cells were fixed, stained and the GI50 for each drug was calculated. Student’s t test (one-tailed) compares the average GI50 for mutBRAF
cell lines vs mutNRAS cell lines. Aminopterin: **p = 0.0092; Pyrimethamine: **p = 0.0071; Methotrexate: ***p = 0.0002. D, Comparison of the IC50
for dypirimethamine of 11 mutBRAF and 7 mutRAS melanoma cell lines, as determined by MTS assay in [25]. *p = 0.0393. E, Graph comparing the
IC50 for dypirimethamine between 22 mutBRAF and 22 mutNRAS cell lines from different tumor types [25]. Student’s t test,
two-tailed: *p = 0.0184.
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that mutNRAS melanoma cells are significantly more
efficient in nucleotide salvaging.
Increased IMPDH2 expression in cancer cells has been
linked to resistance to methotrexate in osteosarcoma,
colorectal and erythroleukemia cells [36-38]. However, al-
though IMPDH2 is overexpressed in melanoma compared
to benign melanocytic lesions (not shown), its expression
did not differ in mutNRAS and mutBRAF melanoma cells.
Therefore, the difference in the response to IMPDH inhib-
itors rather suggests that IMPDH activity or its down-
stream signalling is regulated differently in mutNRAS
compared to mutBRAF cells. Apart from IMPDH, we also
show that thymidine can compensate for DHFR inhibition
in resistant mutNRAS cells, which express higher levels of
TK1. Whether elevated TK1 expression is directly regu-
lated by NRAS is not yet known, but it will be crucial to
identify the underlying mechanism. Importantly, we did
not find differences in TK2 expression between mutNRAS
and mutBRAF cells (not shown), which is maybe not sur-
prising considering the more ubiquitous role of TK2 [39].
Historically antifolate drugs such as methotrexate or
edatrexate have shown very little activity in clinical trials
with melanoma patients although these trials were per-
formed before the discovery of BRAF and RAS as drivers
of melanomagenesis [40,41]. The lack of response in mel-
anoma patients can be explained by several mechanisms
of resistance such as melanosomal sequestration of drugs,
the upregulation of both DHFR and the pro-survival tran-
scription factor MITF in response to MTX, or the E2F
and Chk1 mediated effects, as recently described [42-45].
Despite the inherent capacity to resist any chemotherapy
our data suggest that stratifying patients according to their
BRAF/RAS mutation status could lead to better responses
to antifolate based therapies.
Importantly, our findings suggest that the correlation be-
tween NRAS and BRAF mutations and their differential re-
sponse to antifolate drugs might apply to other cancer
types. Therefore, in cancer types where antifolate based
therapies contribute to achieve clinical responses in RAS
patients (e.g. colorectal carcinoma) [46], it would be inter-
esting to assess whether mutBRAF patients show even im-
proved responses. If that were the case it would open the
possibility to use mutational status as a predictor of patient
response. In summary, our findings identify the mutually
exclusive NRAS and BRAF mutation status as possible pre-
dictive marker for the response to DNA synthesis inhibitors
such as antifolate drugs in melanoma patients.
Conclusions
In summary in this study we demonstrate that activation
of DTIC with white light does not result in a methylat-
ing agent but in to an inhibitor of purine synthesis. We
show that RAS mutant melanoma cells are more resist-
ant to drugs affecting DNA synthesis than BRAF mutant
cells. Our data suggests that, the increased resistance to de
novo DNA synthesis inhibitors found in RAS mutant cells
is due to a superior capacity to salvage DNA. Notably our
results suggest the possibility that the correlation between
RAS and BRAF mutations and the response to antifolate
drugs might be relevant in other cancer types although
further efforts to confirm this hypothesis are warranted.
Materials and methods
Cell culture
Nine mutant BRAF cell lines and nine mutant NRAS cell
lines were used in the study (Additional file 1: Table S1).
These cells were a kind gift from Dr. Richard Marais and
Dr. Adam Hurlstone. Cell stocks were expanded, frozen,
and kept in liquid nitrogen. New aliquots were thawed
every 57 weeks. Cells were cultured in Dulbeccos Modi-
fied Eagles Medium (DMEM) (SIGMA) or in RPMI-164
medium (RPMI) (SIGMA) as previously indicated, supple-
mented with 0.5% penicillin and streptomycin (SIGMA)
and 10% bovine calf serum (PAA, Yeovil, UK). Cells were
grown at 37°C in a 5% CO2 environment.
Reagents
HAT supplement (50X) was from Sigma. Dacarbazine, car-
mustine, cisplatin and temozolomide and lomeguatrib were
from SIGMA. Hypoxanthine, guanosine and 5-guanosine
monophosphate were from Sigma. AZD6244 was from Sell-
eck Chemicals, Newmarket, UK. Mycophenolic Acid and
AVN944 were from Sigma and ChemieTek respectively.
Aminopterin, pyrimethamine and amethopterin (methotrex-
ate) were from Sigma. All drugs were dissolved in dimethyl-
sulfoxide (DMSO) and, apart from dacarbazine, directly
added to cell in culture at the indicated concentrations.
Prior to addition onto cells DTIC was exposed to white light
for 1 h, as previously described [28,30].
Determination of MGMT activity
Melanoma cell free extracts prepared from 106 cells were
analysed for MGMT activity using calf thymus DNA meth-
ylated in vitro with N-nitroso-N-[3H]-methylurea (~20 Ci/
mmol) as the substrate [47]. MGMT activity was expressed
as fmol/μg DNA to avoid the possible effect of variable pro-
tein content on apparent MGMTactivity expressed per unit
protein [48]. No significant differences in the study results
were noted when MGMT activity was expressed per unit
protein. Results are the mean of quadruplicate determina-
tions for each sample. Cell free extracts prepared from the
human breast cancer cell line MCF-7 were assayed for
MGMTactivity as a positive control.
Determination of O6-methylguanine levels in DNA
O6-methylguanine (O6-meG) in DNA was quantified
using a modification of the standard MGMT activity assay
procedure [49]. Increasing amounts of the DNA samples
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were pre-incubated with a standard amount of purified re-
combinant human MGMT [50] and residual activity was
then determined. O6-meG in DNA stoichiometrically in-
activates MGMT. Thus the amount of O6-meG in the
DNA sample equals the amount of inactivation of the
purified MGMT.
Determination of GI50
To determine the drug concentration necessary to inhibit
cell growth by 50% (GI50), 2000 cells per well were plated
in 96 well plates (Corning). After 24 hours, drugs were
added in triplicates in serial 1:3 dilutions. In experiments
where cells were co-treated with the MGMT inactivating
agent lomeguatrib, the drug was added 1 hour before the
addition of serial dilutions of DTIC or TMZ. After 3 or
5 days cells were washed with PBS and simultaneously
fixed and stained for 1 hour with 4% Formaldehyde (Fisher
Scientific) and 0.5% Toluidine Blue (Fluka Analytical) in
PBS. Plates were washed, dried and the dye was solubilized
with 1% Sodium dodecyl sulfate (SDS) (Fisher Scientific)
in PBS. Finally, a spectrophotometer (BIO-TEK®, North-
Star Scientific) was used to measure the O.D. and GI50
values were calculated using the GraphPad Prism software
(GraphPad Software, 4.0a).
Databases
To study the expression profile of APR1, HPRT1 and
TK1 genes in human melanoma versus normal skin or
benign nevus, and to compare TK1 expression between
mutBRAF and mutRAS human melanoma cell lines we
used Oncomine Cancer Microarray database (http://
www.oncomine.org/).
RNA isolation and qPCR analysis
RNA was isolated with TRIZOL® and selected genes
were amplified by quantitative real time PCR using
SYBR green (Qiagen, Valencia, CA, USA).
Primers sequences were:
TK1:
Forward: 5-TGGCTGTCATAGGCATCGAC-3,
Reverse: 5-CCAGTGCAGCCACAATTACG-3
BETA-ACTIN:
Forward: 5-GCAAGCAGGAGTATGACGAG-3,
Reverse: 5-CAAATAAAGCCATGCCAATC-3
EdU incorporation assays
Cells were labelled with 10 μM EdU (Invitrogen) for 4 h
before they were formalin fixed and processed following
the manufacturers instructions. Stained cells were ana-
lysed using a BDpathway 855 Bioimager.
FACS analysis
100000 cells were treated as indicated, fixed in ice-cold 80%
ethanol. Cells were then washed in PBS and incubated in a
solution containing PBS, RNase A and Propidium Iodide
(SIGMA) at 37°C for 1 hour. The analysis was performed
using FACS Calibur (Becton Dickinson).
Statistical analysis
Unless indicated otherwise, data are from assays per-
formed in triplicate, with error bars to represent standard
deviations or errors from the mean. Statistics used were:
predominately Student t-test and One-way ANOVA with
Dunnetts Multiple Comparison Test performed using
GraphPad Prism version 4.00 for Mac OS, GraphPad Soft-
ware, San Diego California USA, www.graphpad.com.
Additional files
Additional file 1: Table S1. List of melanoma cell lines used in this
study, grouped upon the presence of activating mutations in either BRAF
or RAS.
Additional file 2: Figure S1. A, DTIC exposure to white light increases
DTIC’ inhibitory effect.
Additional file 3: Table S2. MGMT status of a panel of 10 melanoma
cell lines MGMT activity in 5 mutBRAF and 5 mutNRAS melanoma cell
lines. Exponentially growing cells were harvested, gDNA was isolated and
the presence of MGMT activity as well as the concentration of MGMT
was determined. N.d.: not detectable.
Additional file 4: Figure S2. 2-Azahypoxanthine and light activated
DTIC show similar UV absorbance profiles.
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